Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2018 Jan 23;7(4):e1296996. doi: 10.1080/2162402X.2017.1296996

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2018 The Author(s). Published with license by Taylor & Francis

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 7. — Targeting both the CD137 and S100A4 pathways in mice diminishes liver toxicity but retains antitumor immunity. Three groups of C57BL/six mice (n = 5 per group) were treated with RatIg, 2A, or 2A plus anti-S100A4 mAb 4 times on days 8, 11, 14, and 18. (A) The kinetics of tumor growth in these three groups are shown. **p < 0.01. (B) Serum ALT levels in these three groups are shown. Day 0 represents the first day of 2A injection. *p < 0.05. (C) Liver tissue collected 7 or 14 d after the first injection of 2A were stained with H&E and Sirius red. Representative FACS data showing the proportions of CD4⁺ T cells and CD8⁺ T cells and statistical analysis of CD8⁺ T cells in the (D) tumor and (E) liver. *p < 0.05. (F) Representative IHC staining for CD8⁺ in tumor sections from different groups.